About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

Our lead investigational product candidate, AFREZZA®
(pronounced uh-FREZZ-uh)
is a novel, ultra rapid-acting mealtime insulin therapy being studied for the treatment of adult patients with Type 1 and Type 2 diabetes mellitus for the control of hyperglycemia. More >

 

Spotlight

MannKind is currently recruiting adult patients with type 1 or type 2 diabetes for two new clinical trials.

If you would like more information, click here to locate a clinical investigator in your area and contact the site directly.

News & Events

   
Feb 22, 2012 MannKind Corporation Reports 2011 Fourth Quarter and Full Year Financial Results More >
Feb 15, 2012 MannKind Corporation to Hold 2011 Fourth Quarter and Full Year Financial Results... More >
Feb 08, 2012 MannKind Announces Exercise In Full of Over-Allotment Option and Completion of Public... More >